Skip To Main Content
Yingke Liang on Muck Rack

Yingke Liang

As seen in: Nature, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingke

Contact Yingke, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Chemo-photothermal synergy ignites antitumor immunity via ferroptosis

|
By Jundong Lin, Zhihao Zou, Lizhi Deng, Xiaoxia Cai, Muqi Chen, Jiaquan Xu, Wenjun Yin, Biyan Wen, Wenjie Xie, Qianfeng Xu, Guowei Zhong, Zhenjie Wu, Yanfei Chen, Rihong Zhang, Weicheng Tian, Yixun Zhang, Yize Li, Yuxiang Liang, Jianheng Ye, Jianming Lu, Yingke Liang, Fen Zou, Huikang Yang, Yusen Long, Zhaodong Han, Qishan Dai, Huichan He, Weide Zhong, Yangjia Zhuo
| Nature Verified
Abstract Docetaxel (Doc), a widely used chemotherapeutic agent, was limited by suboptimal therapeutic efficacy and dose-limiting systemic toxicity due to the insufficiency of hydrophilicity and tumor-targeting specificity.
Open in Who Shared Issue with article?

Structure of Mycobacterial NDH-2 Bound to a 2-Mercapto-Quinazolinone Inhibitor

|
By Yingke Liang, Stephanie A. Bueler, Gregory Cook, John L. Rubinstein
| dx.doi.org
Open in Who Shared Issue with article?

Structure of mycobacterial NDH-2 bound to a 2-mercapto-quinazolinone inhibitor

|
By Yingke Liang, Stephanie A. Bueler, Gregory Cook, John L. Rubinstein
| BioRxiv
Abstract The mycobacterial type II NADH dehydrogenase (NDH-2) is a promising drug target because of its central role in energy metabolism in Mycobacterium tuberculosis and other pathogens, and because it lacks a known mammalian homologue. However, the absence of structural information on how the enzyme binds inhibitors has made optimization of lead compounds challenging.
Open in Who Shared Issue with article?
See all 6 articles